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Abstract
Objective—To determine the effects of gastric bypass on myocardial lipid deposition and 
function and the plasma lipidome in women with obesity and heart failure with preserved ejection 
fraction (HFpEF).
Methods—A primary cohort (N=12) with HFpEF and obesity underwent echocardiography, 
magnetic resonance spectroscopy before, and 3- and 6-mos after bariatric surgery. Plasma 
lipidomics were performed on pre- and 3-mo post-surgery in the primary cohort and confirmed in 
a validation cohort (N=22).
Results—After surgery-induced weight loss, Minnesota Living with Heart Failure questionnaire 
scores, cardiac mass, and liver fat decreased (P < 0.02, < 0.001, = 0.007); echo-derived e′ 
increased (P = 0.03), but cardiac fat was unchanged. Although weight loss was associated with 
decreases in many plasma ceramide and sphingolipid species, plasma lipid and cardiac function 
changes did not correlate.
Conclusions—Surgery-induced weight loss in women with HFpEF and obesity is associated 
with improved symptoms, reverse cardiac remodeling and improved relaxation. While weight loss 
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associated with plasma sphingolipidome changes, cardiac function improvement was not 
associated with lipidomic or myocardial triglyceride changes. Our study results suggest that 
gastric bypass ameliorates obesity-related HFpEF and that cardiac fat deposition and lipidomic 
changes may not be critical to its pathogenesis.
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Introduction
Obesity is a major risk factor for developing heart failure (HF), especially ‘heart failure with 
preserved ejection fraction’ (HFpEF) (1). Women are particularly at risk of developing 
HFpEF(1). Unlike HF with reduced ejection fraction (HFrEF), obesity-related HFpEF is 
increasing in prevalence in the United States. Because the pathophysiology of HFpEF and 
HFrEF may be different, these diseases may require distinct therapeutic approaches. 
Currently, no therapies improve survival in HFpEF (1).
Studies in animal models of obesity show that dysfunction of organs, such as the heart and 
liver, is pathophysiologically linked to excessive fat uptake and storage, and specific waxy 
lipids such as ‘ceramides,’ via a process known as “lipotoxicity”(2). Although there are 
likely multiple mechanisms underlying obesity-related HFpEF, myocardial total ceramides 
and toxic lipid species may play a role (3). Obesity in humans, without HF, is associated 
with cardiac dysfunction, and elevated plasma ceramide levels, myocardial fat uptake and 
storage (4–6). In contrast, weight loss in patients without HF is associated with decreased 
plasma triglyceride and ceramide levels (6), decreased myocardial fat utilization (7) and 
storage,(8) left ventricular (LV) mass, and improved cardiac function (7). Furthermore, 
gastric bypass-induced weight loss is associated with decreased cardiovascular death rates 
(9). However, in HF patients, obesity has been purported to have a protective effect because 
obese patients live longer than lean patients (10, 11). Thus, it is not clear whether patients 
with obesity-related HFpEF should, in fact, lose weight. Recent data show that in animals 
with obesity and HF, myocardial triglyceride and LV mass are increased and diastolic 
function is impaired and these abnormalities improve with weight loss, suggesting a benefit 
of weight loss even in presence of heart failure (12). Whether the same is true in humans 
with HFpEF is not clear. It is also not clear if weight loss in patients with HFpEF decreases 
plasma ceramide levels and sphingolipids.
The aim of this study was to determine the effect of gastric bypass-induced weight loss on 
HF symptoms, myocardial fat deposition, and on the plasma lipidomic profile in women 
with obesity. We also analyzed plasma lipidomic changes in a validation cohort that 
underwent gastric bypass surgery. To this end, we prospectively studied women with HFpEF 
before and 3 mo and 6 mo after gastric bypass surgery using HF questionnaires, magnetic 
resonance spectroscopy, echocardiography, and mass spectrometry. We hypothesized that 
weight loss in women with obesity and HFpEF would improve HF symptoms, diastolic 
function, decrease myocardial fat deposition, and alter plasma levels of ceramides and 
sphingolipids.
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Methods
Subjects – Primary Cohort
The study was approved by the Washington University School of Medicine Human Research 
Protection Office. All patients gave written, informed consent before participating. The 
primary cohort was recruited from the bariatric surgery center at Washington U. School of 
Medicine. Inclusion criteria: women, between 35–65 years of age, BMI>35kg/m2, a 
diagnosis of HFpEF (as determined by two physicians using the patient’s medical history, 
physical exam, echocardiography, and in accordance with diagnostic criteria outlined by 
Eggebeen et al. based on the ACC/AHA guidelines)(13). Exclusion criteria: current tobacco 
use, not ambulatory/able to lie flat for procedures, pregnancy or lactation, cardiac conditions 
that interfered with assessment of diastolic function (e.g., constrictive pericarditis or atrial 
fibrillation/flutter), contraindication to magnetic resonance spectroscopy, other major 
systemic disease except than type 2 diabetes, ejection fraction <50%, uncontrolled 
hypertension, significant pulmonary hypertension by history and/or echocardiography, 
and/or evidence of ischemia on screening stress echocardiogram.
Twenty-four patients were in the primary cohort. Eleven dropped out or were screen failures: 
9 for personal or financial reasons, 1 due to Crohn’s disease activation, and 1 due to a 
positive stress test. Of the remaining 13 patients, one was not used in the final analysis due 
to uninterpretable echocardiographic data.
Experimental Procedures
Primary cohort patients were extensively screened and phenotyped before surgery for 
evaluation of HF symptoms and signs and determination of New York Heart Association 
(NYHA) HF class. Patients underwent phlebotomy while fasting for a comprehensive 
metabolic panel, complete blood count, cholesterol profiles, glucose, and sphingolipid and 
ceramide measurement pre-surgery and 3 and 6 mo after surgery. All subjects were in energy 
balance when their pre-surgery measurements were made. A Minnesota Living with HF 
(MNLHF) Questionnaire was administered to assess symptomatic limitations from HF. The 
MNLHF 100-point scale questionnaire is a well-validated tool used in many HF clinical 
trials (14). A higher score indicates worse HF symptoms and a score of ‘0’ indicates no 
symptoms. As a reference, prior validating studies have correlated HFpEF patients with 
scores to 15–48 to NYHA class II and scores of 32–67 to NYHA class III (14, 15). All 
patients underwent dual-energy X-ray absorptiometry (Lunar iDXA, General Electric, 
Fairfield Connecticut) for fat mass and fat-free mass measurement. All subjects underwent a 
rest and stress echocardiogram.
Echocardiography
Resting echocardiograms pre-surgery were used to evaluate cardiac structure and function. 
LV mass was measured using the area-length method. Relative wall thickness was calculated 
as (2*posterior wall thickness)/LV end-diastolic diameter. LV ejection fraction was 
calculated using the modified Simpson’s method. Mitral valve inflow E wave was measured 
using spectral Doppler, and tissue Doppler was used to quantify early relaxation e′ at both 
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the septal and lateral mitral valve annulus. These were averaged to obtain an e′ average. E/e
′, a measure of left atrial pressure was calculated. Echocardiography was repeated at 3 mo 
and 6 mo after surgery. (The U. of Texas cohort also had E and e′ average measured at 
baseline.)
1H-Magnetic Resonance Spectroscopy
The validation and reproducibility of 1H-magnetic resonance spectroscopy technique have 
been published previously by our group and others (5, 16). Magnetic resonance spectroscopy 
was used to measure myocardial and hepatic tissue lipid as described previously by our 
research group (17). Cardiac spectra were acquired from the interventricular septum at end-
systole and at end-respiration. Liver spectra were obtained from a region of interest in the 
right lobe of the liver that did not include visible vasculature. The spectra were analyzed 
using AMARES fitting programs and jMRUI software. 1H-magnetic resonance spectroscopy 
was performed before, and 3 mo and 6 mo after surgery in the primary cohort. The regions 
of interest in subsequent scans were placed as close to the original regions as possible.
Roux-en-Y Gastric Bypass Surgery
The same surgeon (JCE) performed all of the gastric bypass surgeries for the primary cohort. 
In brief, stapling across the stomach created a small gastric pouch. A Roux-en-Y limb was 
then constructed by cutting across the jejunum distal to the ligament of Treitz and creating a 
jejunojejunostomy distal to the transection.
Lipidomics
Liquid chromatography-tandem mass spectrometry was used to analyze pre-surgery and 3 
mo post-surgery plasma samples for long-chain and very-long-chain ceramides and 
sphingomyelins at the Washington University Metabolomics Facility. The reagents, sample 
preparation, instrumentation, internal standards, and quantification methods were previously 
described in detail in Fan et al. (18) and are shown in Table S1 (supplemental). Analyses 
were carried out blinded to subject treatment phase on samples from the initial Washington 
University cohort and on samples from a validation cohort of women undergoing gastric 
bypass at the University of Texas-Houston. Eight subjects in the primary cohort and 22 in 
the validation cohort had plasma samples at the pre- and 3 mo post-surgery timepoints. The 
validation cohort was added because the primary cohort was relatively small, and this is one 
of the first studies of lipidomic effects of weight loss. The validation cohort had significant 
obesity but they were not evaluated for signs and symptoms of HFpEF pre-operatively. 
Validation analysis focused on lipid species that were significantly different after weight loss 
in the St. Louis cohort and had a coefficient of variation less than 10%.
Statistical analysis
Data were analyzed using SAS v9.3 (SAS Institute Inc., Cary, NC). Data are presented as 
mean ± SE. A repeated measures analysis based on a mixed model approach was conducted 
to examine change in patient characteristics and heart function measures over time (pre, 3- 
and 6-mo after gastric bypass surgery). Mean estimates were obtained from the model 
results. All pair-wise comparisons were made and a Bonferroni adjustment was applied 
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when reporting P values. The Houston data contained 2 measurements per subject per time-
point. A repeated measures analysis based on a mixed model approach was used to account 
for correlated data within subject at each time point and across time points (pre-surgery and 
3 mo post). Mean estimates and comparisons between time-points were obtained from 
model results. Pearson correlations were created to describe the linear relationship between 
the change in heart function and change in lipidomic species. Comparisons of the baseline 
characteristics of both cohorts were done with unpaired t-tests. Statistical significance was 
set at P <0.05.
Results
Baseline characteristics
The primary cohort data are shown in Table 1. The average age of the women was 47 years, 
all had at least class II obesity, and on average ~44% of their body mass was fat mass. 
Patients scored relatively poorly on the Minnesota Living with HF score (MLWHF) quality 
of life questionnaire (27 ± 6), which objectifies symptoms of HF (Figure 1). Eight subjects 
had type 2 diabetes and most were taking insulin or hypoglycemic agents (Table 2). 
Similarly, although the subjects’ hemodynamics were in the normal range, most were taking 
at least one vasoactive and/or diuretic medication.
There were several echocardiographic abnormalities at baseline. Although all subjects had 
normal ejection fractions, their LV mass was severely increased (Figure 2) (19–21). (The 
normal range of LV mass in women is 66–150g with severe hypertrophy > 193g). This, in 
combination with increased relative wall thickness, is consistent with concentric LV 
hypertrophy (LVH) (19, 21). The subjects’ average early cardiac relaxation, (average septal 
and lateral e′ of 9.5±0.6) was abnormal for women in their 40s (normal 14.2 ± 2.3) (20), 
though E/e′ was borderline normal (8.2 ± 0.5, normal being < 8; see Table 1).
Weight Loss and Metabolism, Hemodynamics, and Medications
Three and six months after gastric bypass surgery, there was progressive weight loss 
accompanied by significant improvements in resting heart rate (Table 1) despite fewer 
subjects taking beta-blocker medications (Table 2). Although there was no significant 
difference in plasma glucose or blood pressure, fewer subjects took antihypertensive and 
glucose-lowering medications after weight loss. The validation cohort also experienced 
metabolic improvements (Table 3), namely, lower total cholesterol, fasting glucose and 
insulin levels. High-density lipoprotein levels also decreased.
Weight Loss and HF symptoms
Patients also experienced fewer HF symptoms as evidenced by the decrease in the MNLHF 
score (Figure 1) and NYHA class (Figure 3), suggesting that they were able to perform more 
activities with fewer HF symptoms.
Weight Loss and LV Structure/Function
LV mass regressed significantly, although it was still above normal six months after surgery 
(Figure 2). Relative wall thickness also decreased (Table 1). The abnormally low LV 
Mikhalkova et al. Page 5
Obesity (Silver Spring). Author manuscript; available in PMC 2018 June 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
relaxation, (e′), improved with weight loss (Table 1). The borderline normal baseline left 
atrial filling pressure (E/e′) trended toward an improvement (Table 1).
Weight Loss and Steatosis
Patients in this study had high baseline hepatic fat content, 18.97±3.37% — well above the 
upper limit of normal (5.56%)(Table 1) (5, 22, 23). Hepatic fat decreased with weight loss 
(Table 1). Six months after surgery, hepatic fat was within normal levels. In contrast, cardiac 
fat content was much lower than hepatic fat at baseline and did not change after the surgery.
Weight Loss and Lipidomic Results
Four ceramides and 12 sphingomyelins in the primary cohort decreased after 3 mo of weight 
loss. Four Sphingomyelins and one ceramide (18:0) increased after 3 mo. All species that 
changed significantly in both cohorts and which had the prerequisite coefficient of variation 
less than 10% are shown in Table 4. (Other ceramides and sphingolipids are listed in 
Supplementary Table 1). The Houston cohort had a higher baseline BMI 50.4 ± 9.7 kg/m2 
(P=0.02) but was not different in age, sex, blood pressure, or fasting glucose. Ejection 
fraction, e′ and E/e′ were also not different at baseline from the primary cohort (data not 
shown). The Houston cohort’s metabolic profile improved 3 mo after surgery, like the 
primary cohort (Table 3). Again, most of the ceramide and sphingolipids species tested 
decreased after 3 mo of weight loss. Three of the four sphingomyelins that increased in the 
primary cohort (SM18:0, SM24:1, SM24:2) also increased in the validation cohort. The only 
lipid species that did not change in the same direction in the validation cohort and the 
primary cohort was the odd-chain, SM23:1, which decreased in the primary cohort and 
increased in the validation cohort. None of these lipidomic changes correlated with 
improvement in diastolic function as assessed by e′.
Discussion
In this study we showed that gastric bypass-induced weight loss ameliorated symptoms of 
obesity-related HFpEF, reversed adverse LV remodeling, improved diastolic function, and 
was associated with alterations in the plasma lipidome in women. Surgery-induced weight 
loss also improved symptoms and quality of life as assessed by the MNLWHF and NYHA 
scores. Weight loss improved cardiac structure, specifically, LV mass and relative wall 
thickness, and LV relaxation as assessed by e′. Moreover, weight loss decreased liver fat and 
plasma levels of several sphingolipids, which have generally been implicated in lipotoxicity 
in animal models (2,24). The changes in plasma sphingolipids were largely replicated in a 
validation cohort. However, the lipidomic changes in the primary cohort did not correlate 
with the diastolic function improvements. Weight loss did not alter cardiac but did decrease 
hepatic triglyceride content. Thus, it appears that triglyceride deposition may not be critical 
to the pathogenesis of human, obesity-related HFpEF.
Currently few therapies have been shown to improve symptoms for HFpEF (26), which is 
why the results after gastric bypass-induced weight loss shown in our study are so striking. 
The baseline MHLHF score was 27±6, which decreased to 7±6 after weight loss, and weight 
loss improved the average NYHA class. Our results are also in line with a recent finding of 
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reduced emergency room visits and HF hospitalizations after bariatric surgery in patients 
with obesity-related HFpEF (25). Importantly, gastric bypass-induced weight loss improves 
symptoms and quality of life without increasing heart rate or other cardiac markers of 
increased mortality, unlike other treatments of HF, such as adrenergic agonists.
Our study showed improved hemodynamics, LV structure and function after weight loss in 
patients with obesity-related HFpEF. It is already well-known that these parameters improve 
with weight loss in obesity without HFpEF (6). Decreased resting heart rate is an especially 
important finding because high resting heart rate is a well-known marker of poor outcomes 
(27) and because the decrease in heart rate occurred despite fewer patients taking beta-
blockers after weight loss. In addition, subjects needed less antihypertensive medication to 
maintain a normal pressure (Table 2). Recent data from a study in obese animals with HF 
show that weight loss improved LVH and diastolic function (12). Our data in humans is 
similar, showing that there was significant reduction in LV mass and relative wall thickness. 
However, though mean relative wall thickness normalized, LV mass did not. A longer follow 
up and greater weight loss may be required for both parameters to normalize. Reduction in 
LVH is an especially important endpoint in women because it has been linked to higher risk 
of cardiovascular fatal outcomes when compared to men (28). LVH regression is also linked 
with reduced HF hospitalizations, and improved diastolic function (29, 30). Active 
relaxation (e′) in diastole also improved (Table 1). This is a notoriously difficult parameter 
to influence with any therapy. For example, in the VALIDD study, aggressive blood pressure 
control with valsartan resulted in only a 0.6cm/s change from baseline but was not different 
from the placebo-treated group(31). Interestingly, the improved LV relaxation and decrease 
in heart size in patients with HFpEF occurred without a change in blood pressure and in 
spite of fewer patients taking antihypertensive medications after weight loss. The 
improvements in markers of poor prognosis (increased LV mass and resting heart rate) after 
weight loss appear to contradict the complex, and likely multifactorial, ‘obesity paradox,’ in 
which subjects with HF and obesity have a better prognosis than those without obesity. 
However, our findings of the beneficial effect of weight loss on survival rates are supported 
by 2 large studies (N>13,000) of gastric bypass (9, 32).
Despite the change in LV mass, as well as marked weight loss and marked decreases of 
hepatic lipid (Table 1) the amount of myocardial lipid did not change. In our study, baseline 
cardiac lipid was ~1.18 %, which was higher than reported values in normal subjects 
~0.4±0.2% (16). This is in contrast to several studies in animal models of obesity that 
suggest excessive fat deposition is a key element in the development of toxic lipid species 
(such as some ceramides), lipotoxicity, and cardiac dysfunction (2). This is also in contrast 
to a study of diet-induced weight loss in patients with type 2 diabetes, which showed a 
decrease in myocardial lipid content, although this decrease did not correlate with the 
improvement in diastolic function (7). Our findings suggest that while myocardial 
triglyceride stores reflect the altered metabolic environment of obesity, the triglyceride itself 
may not be a major mediator of cardiac dysfunction, a notion that has been supported by 
findings in cultured cells (33) and rodent models of lipotoxic cardiomyopathy (34). The 
precise nature of lipotoxic species in the obese heart remain to be determined but changes in 
the plasma sphingolipids suggest these could include some ceramides and sphingomyelins. 
Decrease in hepatic triglyceride, but not cardiac triglyceride, 6 months following bariatric 
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surgery may reflect a more dynamic pool of lipid in the liver. The liver also moves less than 
the heart, and so is easier to image than the heart. It is also likely to be easier to detect a 
difference in the liver fat of our subjects after weight loss given that liver fat content was 18-
fold higher than cardiac fat at baseline. Thus, it appears that myocardial oxidation (6) and/or 
processing of fatty acids, which can yield reactive oxygen species (24) and/or toxic lipid 
species – such as some ceramides (2, 3)—may play a more important role in obesity-related 
cardiac dysfunction than lipid deposition.
In the current study, we found that the plasma ceramides and sphingolipids levels change 
after gastric bypass-induced weight loss in HFpEF patients. The majority of sphingolipids 
and ceramides decreased, but a few increased after 3 mo. Our findings were replicated in a 
validation cohort of patients from UT-Houston, who also underwent gastric bypass. We did 
not find a correlation between the plasma lipidomic changes and the improvements in LV 
mass or function. A few other studies evaluated specific lipid changes after bariatric surgery, 
though none in HFpEF patients, and no studies evaluated their possible relationship with 
cardiac indices (35, 36). Generally, a decrease was found in ceramides after gastric bypass 
surgery (36), although changes in specific ceramide species vary somewhat among the 
studies. E.g., in the study by Huang, ceramides 14:0, 16:0, 20:0, and 24:0 were decreased at 
3 and 6 mo post-op (35) whereas we found decreases in ceramides 22:0, 23:0, 24:0, and 
25:0. There are some indications that certain ceramides, and possibly sphingomyelins, may 
be associated with favorable outcomes and others may be associated with adverse outcomes 
in patients referred for cardiac catheterization (37). However, more long-term research on 
the prognostic role of ceramides/sphingomyelins in patients with obesity, HFpEF, after 
weight loss, and in population studies is required. The lipidome during short-term weight 
loss may also be different than after weight stabilization for years.
Limitations
Our study is limited by small numbers and by the relatively short duration of follow-up. 
Although the UT-Houston cohort was similar to the primary cohort in several baseline 
characteristics and had very similar lipidomic changes, the former was not rigorously 
evaluated for signs and symptoms of HFpEF. Thus the comparison of the 2 groups is not 
perfect. The results of our study cannot automatically be extended to men or other subjects 
who do not fit our entry criteria. We limited our study to women because they make up the 
vast majority of subjects who undergo gastric bypass surgery and because of the known 
myocardial metabolic differences between men and women who are obese (38). MR 
spectroscopy evaluation of steatosis is generally validated for measuring triglyceride 
accumulation and does not yield information regarding other lipid species deposition, such 
as ceramides.
Conclusion
Gastric bypass surgery-induced weight loss in women with obesity-related HFpEF results in 
improvement of HF symptoms and diastolic function. Surgery-induced weight loss also 
decreases LV mass and resting heart rate, which are associated with increased mortality. 
These data suggest that gastric bypass may alleviate HFpEF in patients who are obese. 
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Moreover, there are intriguing alterations in the plasma lipidome in HFpEF after gastric 
bypass surgery. Future studies are needed to clarify the pathogenesis of these changes and 
whether they have potential to serve as biomarkers of cardiac and whole body function or 
whether they may impact function themselves.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is already known about this subject?
• Studies in animal models of obesity show that excessive fat deposition and 
specifically certain lipid species (including ceramides), in the myocardium is 
highly correlated with cardiac dysfunction.
• Total ceramides are increased in the myocardium of patients with heart failure 
and decreased after left ventricular (LV) assist device therapy.
• Obesity in humans is associated with elevated plasma ceramide levels and an 
increased risk of cardiac dysfunction and heart failure — particularly heart 
failure with preserved ejection fraction (HFpEF).
What does our study add?
• Our study shows for the first time that gastric bypass-induced weight loss 
improves symptoms of heart failure as well as diastolic function and other 
prognostically important measures (LV mass and resting heart rate) in patients 
with obesity-related HFpEF.
• This improvement in obesity-related HFpEF is associated with changes in 
specific plasma ceramide levels but no change in myocardial triglyceride 
content.
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Figure 1. 
Minnesota Living with Heart Failure (MNLWHF) score changes with weight loss.
MLWHF scores (mean ± SE) decreased significantly from pre-surgery, to the post-surgery 
for the St. Louis cohort (overall trend P=0.02). Lower MNLWHF scores are indicative of 
fewer heart failure symptoms.
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Figure 2. 
LV mass changes from Pre Surgery to 3 and 6 months after bariatric surgery.
LV mass decreased after weight loss at 3 mo and 6 mo after surgery. Data shown are mean ± 
SE.
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Figure 3. 
New York Heart Association (NHYA) Classification changes for the St. Louis cohort after 
surgery.
NYHA classification pre-surgery and 3- and 6-mo post-surgery. A lower NYHA 
classification number indicates improved functional capacity.
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Table 2
Vasoactive, diabetes, and lipid medications before and after gastric bypass surgery in the primary cohort. 
(Values are expressed as number taking a medication/total patients)
Medication Baseline 3 months post surgery 6 months post surgery
Vasoactive/Diuretic Medication
ACE-Inhibitors/ARBs 7/12 3/10 2/10
Beta-Blockers 3/12 3/10 1/10
Loop/Thiazide diuretic 4/12 1/10 1/10
Diabetic Medication
Oral hypoglycemic 6/12 1/10 0/10
Insulin 3/12 1/10 0/10
Lipid Management
Statins 5/12 4/10 1/10
Other lipid Rx 1/12 1/10 3/10
ACE = angiotensin converting enzyme inhibitor; ARBs = angiotensin receptor blockers; Rx = medication
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Table 3
Metabolic Profile of the UT-Houston patients at baseline and after 3 mo of weight loss
Pre-surgery 3 mo after surgery P value
Total Cholesterol (mg/dL) 176 ± 6 150 ± 6 <0.001
High Density Lipoprotein (mg/dL) 41 ± 2 37 ± 2 <0.001
Triglycerides 155 ± 45 98 ± 9 0.22
Free fatty acids (mmol/L) 0.90 ± 0.05 0.93 ± 0.06 0.67
Fasting glucose (mg/dL) 105.1 ± 9.9 79.4 ± 2.2 0.02
Fasting insulin (IU/L) 20.63 ± 3.85 9.93 ± 0.90 0.01
Data shown as mean ± SE. N = 19; Text in bold font indicates significant P values.
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Table 4
The Sphingomyelins and Ceramides that Changed Significantly at 3 mo post-surgery in the Primary and 
Validation Cohorts Presented as a Fold-change (3 mo – baseline/baseline) from Pre- Surgery Values.
Primary Cohort (WUSM) Validation (UTHouston) Cohort P Value
Ceramide 23:0 −0.48 ± 0.09 −0.28 ± 0.07 0.13
Ceramide 24:0 −0.39 ±0.11 −0.22 ± 0.07 0.24
Sphingomyelin 14:1 −0.39 ± 0.09 −0.24 ± 0.04 0.08
Sphingomyelin 14:0 −0.27 ± 0.09 −0.20 ± 0.04 0.46
Sphingomyelin 18:0 0.22 ± 0.05 0.26 ± 0.07 0.74
Sphingomyelin 20:0 −0.23 ± 0.09 −0.12 ± 0.05 0.32
Sphingomyelin 22:1 −0.17 ± 0.09 −0.09 ± 0.06 0.48
Sphingomyelin 24:2 0.29 ± 0.09 0.34 ± 0.09 0.72
Sphingomyelin 23:1 −0.15 ± 0.08 0.25 ± 0.07 0.003
Sphingomyelin 21:0 −0.41 ± 0.07 −0.26 ± 0.07 0.27
Sphingomyelin 24:1 0.30 ± 0.13 0.36 ± 0.08 0.74
Sphingomyelin 22:0 −0.28 ± 0.09 −0.21 ± 0.06 0.52
Sphingomyelin 23:0 −0.39 ± 0.08 −0.29 ± 0.06 0.38
Sphingomyelin 24:0 −0.27 ± 0.11 −0.22 ± 0.06 0.72
Comparison based on two sample t-tests. N= 8 for Primary cohort, N=22 for validation cohort). Text in bold font indicates a significant P values.
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